Genscript Biotech Corporation
1548
Classement en actions
#2099
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Prix de l'action
$4.37
Capitalisation boursière
$9.84B
Changement (1 jour)
2.30%
Changement (1 an)
109.57%
Pays
HK
Échange Genscript Biotech Corporation (1548)
Catégorie
Healthcare
Bénéfices pour Genscript Biotech Corporation (1548)
Bénéfices en Jun 2026 TTM : $-589.54M
Selon les derniers rapports financiers de Genscript Biotech Corporation, les bénéfices actuels de l'entreprise sont de $-589.54M. En 2023, l'entreprise a réalisé un bénéfice de $-350.98M, une augmentation par rapport à celui de 2022 qui était de $-431.69M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Genscript Biotech Corporation de 2013 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-589.54M | 245.17% |
| 2024 | $-170.80M | -51.34% |
| 2023 | $-350.98M | -18.70% |
| 2022 | $-431.69M | -16.56% |
| 2021 | $-517.36M | 83.53% |
| 2020 | $-281.90M | 147.95% |
| 2019 | $-113.69M | -600.84% |
| 2018 | $22.70M | -41.07% |
| 2017 | $38.52M | 18.49% |
| 2016 | $32.51M | 41.49% |
| 2015 | $22.98M | 193.21% |
| 2014 | $7.84M | 4.08% |
| 2013 | $7.53M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -994.74% |
US
|
|
| $-3.09B | 423.62% |
US
|
|
| $-4.02B | 581.24% |
AU
|
|
| $1.95B | -430.87% |
NL
|
|
| - | - |
CH
|
